Integral Molecular launches protein engineering platform

By Amerigo Allegretto, The Science Advisory Board contributing writer

July 30, 2021 -- Integral Molecular announced the launch of its proprietary protein engineering platform, GeneCanvas, for the optimization of transgenes and other elements that are essential for gene therapy development.

The new engineering platform can achieve tenfold to 100-fold increases in gene activity by improving transgene protein expression, trafficking, stability, and function, according to the company. These enhancements will ultimately result in improved efficacy, smaller doses, and increased safety for patients.

The platform incorporates the company's proprietary high-throughput mutagenesis and human cell-screening platforms to create and screen large libraries of variants. According to Integral Molecular, GeneCanvas provides a detailed analysis of each target to determine the optimal approach for protein engineering and to develop a customized work plan for the customer.

GeneCanvas uses four deep-screening platforms, which perform the following functions:

  • Shotgun mutagenesis and comprehensive affinity mutagenesis are used to create thousands of targeted mutations, which are screened for binding or functional activity in human cells.
  • Random mutagenesis is used to produce millions of variants, along with high-throughput flow cytometry to assess binding in live human cells.
  • A library is created of thousands of mutations in bacteria, and the variants are screened for optimal activity.
  • Using specialized phage protocols, variants are selected that display high-affinity binding.

The company showcased the GeneCanvas platform during the Bio Digital meeting that took place in June.

Integral Molecular, Optimeos partner on long-lasting antibody therapeutics
Integral Molecular and Optimeos Life Sciences have partnered to develop novel antibody therapeutics using long-acting, sustained delivery formulations.
Integral Molecular touts Pa. grant to advance COVID-19 research
Integral Molecular was awarded over $520,000 from the state of Pennsylvania to leverage its technologies in COVID-19 research. The grant will enable the...
Integral Molecular adds to its antibody discovery platform
Integral Molecular has developed humanized chicken antibody technology and incorporated it into its MPS antibody discovery platform for multipass membrane...
Integral Molecular aids with safety testing of COVID-19 antibodies
Integral Molecular is applying its membrane proteome array technology for antibody specificity profiling to accelerate development of SARS-CoV-2 therapeutic...
Integral Molecular wins COVID-19 NIAID award
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Integral Molecular $1 million to help discover vaccines and therapeutics...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter